Axovant Sciences Ltd. (NYSE:AXON) Files An 8-K Other Events

Axovant Sciences Ltd. (NYSE:AXON) Files An 8-K Other Events

Story continues below

Item 8.01 Other Events.

On February13, 2017, Axovant Sciences Ltd. issued a press release
providing preliminary results from interim analysis of its Phase
2 study of nelotanserin in patients with either dementia with
Lewy bodies or Parkinsons disease dementia who experience
frequent visual hallucinations. A copy of the press release
issued is filed as Exhibit99.1 to this Current Report on Form8-K
and is incorporated herein by reference.

Item 9.01 Exhibits.

(d)Exhibits.

ExhibitNo.

Description

99.1

Press Release, dated February13, 2017, Axovant Sciences
Announces Preliminary Results from Interim Analysis of
Phase 2 Study Testing Investigational Drug Nelotanserin in
Lewy Body Dementia Patients.


About Axovant Sciences Ltd. (NYSE:AXON)

Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company’s focus is to develop its lead product candidate, Intepirdine, which is a selective 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing its second product candidate, Nelotanserin, which is a selective 5-HT2A receptor inverse agonist for the treatment of visual hallucinations in patients with DLB and rapid eye movement (REM) behavior disorder (RBD) in patients with DLB.

Axovant Sciences Ltd. (NYSE:AXON) Recent Trading Information

Axovant Sciences Ltd. (NYSE:AXON) closed its last trading session down -0.16 at 12.67 with 315,111 shares trading hands.

An ad to help with our costs